Home
overview

 

 

SMi present their 8th annual Asthma & COPD event to be held in London on Monday 16th & Tuesday 17th of Apil 2012.  Building on the success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, this year will see an elite panel of speakers drawn for both industry and academia.

The successful combination of academic KOLs and leading senior big Pharma speakers offers an ideal and comprehensive platform for the study of both Asthma & COPD.

The similarities between the two conditions are juxtoposed with the the subtle and important differences. Both pose unique and complex challenges, and these differences must be identified and isolated. As respiratory research continues to grow and prosper this event contributes further towards the understanding of how they can be dealt with in a successful and cost effective manner.

This event offers an ideal platform for those who have recently moved in to respiratory studies as well as established professionals. This is an opportunity to network with the leading protagonists in the field and to learn from their knowledge and experience as well as to share your own.

 

 

"The total financial burden of lung disease in Europe amounts to nearly €102 billion, a figure comparable to the annual gross domestic product (GDP) of the Republic of Ireland.
COPD contributes to almost one-half of this figure, followed by asthma, pneumonia, lung cancer and TB"

Source: http://www.european-lung-foundation.org/16-european-lung-foundation-elf-lung-diseases.htm

 

Study comparisons of exacerbations of Asthma & COPD
Analyse the EXACT-PRO initiative and take lessons from it
Investigate POET-COPD studies. What has been learned and what can be taken forward.
Explore novel bronchodilators and how they should be used
Understand combination therapies; clinical and exercise therapies. How can these be used more and more effectively.
Isolate unmet needs in Asthma & COPD and debate how these needs can be met and addressed.
Expand your knowledge of biomarkers in Asthma & COPD - discovery and validation.
Develop and analyse ideas for new end points required for regulatory outcomes

 

 

 

Key Speakers  include:

  • Professor Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine
  • Professor Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine
  • Thys van der Molen, Professor of Primary Care Respiratory Medicine, University of Groningen University Medical Centre Groningen Centre for Medical Biomics
  • Professor Maria Belvisi, Head, Respiratory Pharmacology Group Pharmacology and Toxicology Section, National Heart & Lung Institute
  • Stefano Petruzzelli, Head, Respiratory Medicine Unit Corporate Clinical Development, Chiesi Farmaceutici
  • Louise Donnelly, Reader in Respiratory Cell Biology, National Heart & Lung Institute
  • Professor Wisia Wedzicha, Professor Respiratory Medicine, University College London

 

Industry professionals in positions such as:

 
  • Associate Clinician
  • Associate Director
  • Biomarker Specialist
  • Brand Manager
  • Business Development Director
  • CEO
  • Chief Executive Officer
  • Chief Medical Officer
  • Chief Scientific Officer
  • Clinical & Regulatory Strategy Manager
  • Clinical Pharmacologist
  • Clinical Trial Manager
  • Commercial Director
  • CSO
  • Director
  • Director of Medical Affairs
  • Head Global Licensing Respiratory
  • Head of Clinical Science
  • Head of Discovery
  • Head of Global Data Informatics - Global Preclinical R&D
  • Head of In-Vitro Biology
  • Head of Pharmacology
  • Head of Respiratory Pharmacology
  • Managing Director
  • Medical Affairs Director
  • Medical Director
  • Principal Scientist
  • Vice President
  • VP Chemistry
  • VP Inflammatory Disease Area
  • VP, Clinical Research Immunology
  • VP, Research

  

Attendees at previous SMi Asthma & COPD events include: 3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer,Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synairgen, Topigen, UCB, Vitalograph

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

9:10 Comparing exacerbations of Asthma & COPD

Sebastian Johnston

Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

• What causes exacerbations
• Uniqueness and complexity
• Effective modelling
• Treatments – improving way of life
 

9:50 Unmet Challenges in Asthma

Samantha Walker

Samantha Walker, Executive Director, Research & Policy, Asthma Uk

  • Asthma still has unmet needs
  • Directing research focus ad attention
  • Work of Asthma UK
  • Partnering with academia and industry study
  • 10:30 Morning Coffee

    11:00 CHEMOKINE RECEPTOR CXCR2 ANTAGONISM TO PREVENT AIRWAYS INFLAMMATION

    Louise Donnelly

    Louise Donnelly, Reader in Respiratory Cell Biology, National Heart and Lung Institute Imperial College

    • Neutrophilic inflammation in airways disease
    • Why target CXCR2?
    • Novel CXCR2 antagonists
    • Current trials of CXCR2 antagonists

    11:40 CRTH2 antagonists for the treatment of asthma and allergic rhinitis

    Roy Pettipher

    Roy Pettipher, , Oxagen Ltd

    • Role of CRTH2 in activation of Th2 lymphocytes and eosinophils
    • Identification of highly potent and selective CRTH2 antagonists
    • Clinical effects of CRTH2 antagonists

    12:20 Combination therapy

    Mary Fitzgerald

    Mary Fitzgerald, Research, Pulmagen Therapeutics

    • New ICS/LABA combinations: What and why
    • Switching on Inhaled Corticosteroids: Novel anti-inflammatory combinations
    • Combination bronchodilators: Optimising symptomatic benefit

    13:00 Networking Lunch

    14:00 Novel Data from Asthma Clinical Trials

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

  • Novel data of Asthma Clinical Trials in Primary Care
  • case studies using real data: General Practice research Database (GPRD)
  • Utilisign lessons learned
  • 14:40 Anti-inflammatory therapies in COPD

    Daniel Bock

    Daniel Bock, Chief Scientific Officer, Revotar Biopharmaceuticals

  • Rationale and general considerations
  • Targeting inflammation: options and limitations
  • Translating anti-inflammatory potency into clinical benefit
  • Overview: Emerging drugs in clinical development
  • Positioning anti-inflammatory drugs in the future armamentarium of COPD therapy
  • 15:20 Afternoon Tea

    15:40 MyAsthma: lessons from a live app for asthma patients

    •         Understanding the opportunities
    •         The importance of insight
    •         Connecting insight, medicine and technology to build something useful
    •         Preliminary outcomes
     

    Francisco Abad-Marin

    Francisco Abad-Marin, Marketing Manager, Respiratory Centre of Excellence, GlaxoSmithKline

    Nick Broughton

    Nick Broughton, Consultant Medical Advisor, GSK

    16:20 Panel Discussion: Asthma mechanisms & treatments

    Sebastian Johnston

    Sebastian Johnston, Professor of Respiratory Medicine, Imperial College School of Medicine (N.H.L.I.)

    Roy Pettipher

    Roy Pettipher, , Oxagen Ltd

    Stefano Petruzzelli

    Stefano Petruzzelli, Head of Respiratory Medicine unit, CHIESI FARMACEUTICI S.P.A.

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Peter Barnes

    Peter Barnes, Head of Respiratory Medicine, Imperial College

    9:10 The problem of steroid resistance in Asthma & COPD

    Peter Barnes

    Peter Barnes, Head of Respiratory Medicine, Imperial College

    • Understanding the mechanisms of steroid resistance provides new insights into the mechanism of steroid action as well as the underlying chronic disease process
    • In patients with primary steroid-resistant (SR) asthma there is no abnormality in the pharmacokinetics of the exogenous steroid and no significant defect in steroid binding to the glucocorticoid receptor (GR).
    • Recent studies have demonstrated a marked reduction in the binding of GR to DNA
    • Binding of GR to the transcription factor activator protein-1 (AP-1).
    • Secondary steroid resistance in asthma may arise in response to the release of cytokines that activate AP-1 and other transcription factors that bind directly to GR.
     

    9:50 Using patient reported outcomes (CCQ ACQ) in daily clinical practice; results of the asthma COPD service for General practitioners in The Netherlands

    Thys van der Molen

    Thys van der Molen, Professor of primary care Respiratory Medicine, University of Groningen University Medical Centre Groningen Centre for Medical Biomics

    • Lungs and life tests
    • Patient recorded symptoms & outcomes – reporting on the way to a doctor
    • Netherlands case study
    • Implementation elsewhere

    10:30 Morning Coffee

    11:00 The challenge of COPD exacerbations: how do Patient Reported Outcomes impact in clinical trials design?

    Stefano Petruzzelli

    Stefano Petruzzelli, Head of Respiratory Medicine unit, CHIESI FARMACEUTICI S.P.A.

    • A consortium approach to instrument development
    • Development of single validated PRO
    • Reduction of frequency , severity and duration of exacerbations
    • Search for the Gold Standard
    • Phase I to IV study history
     

    11:40 Co-Morbidities in COPD

    John Hurst

    John Hurst, Senior Clinical Lecturer, University College London

    • Cause and prevention
    • Case study trial evidence
    • Smoking and smoking cessation
    • The ‘whole body’ approach
     

    12:20 Development of a vagus nerve stimulator to treat asthma and COPD exacerbations. A game changing technology?

    Bruce Simon

    Bruce Simon, VP Research, ElectroCore Medical, AB

  • A guinea pig model was used to optimize an electrical signal to the vagus nerve to protect against histamine-induced bronchoconstriction
  • Asthma patients presenting to the ED with exacerbations not responsive to SOC were enrolled in a clinical trial and treated with this signal via a percutaneous electrode
  • Stimulation resulted in significant improvement in FEV1 within minutes of stimulation with no adverse events or changes in BP or HR
  • A non-invasive version of the treatment was developed and tested in a hypersensitive beagle model which demonstrated that two minutes of stimulation could inhibit methacholine-induced bronchoconstriction for more than two hours
  • Preliminary human clinical data shows encouraging improvement in asthma and COPD patients within minutes of treatment, lasting up to 4 – 6 hours
  • 13:00 Networking Lunch

    14:10 The Management of COPD exacerbations

    Neil Barnes

    Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust


    • Causes of COPD Exacerbation: Infection, Air Pollution
    • Signs and Symptoms of a COPD Exacerbation
    • Treatment of COPD Exacerbation
    • Prevention of COPD exacerbation

    14:50 Pre-clinical models of asthma and COPD

    Maria Belvisi

    Maria Belvisi, Professor of Respiratory Pharmacology, National Heart and Lung Institute Imperial College London

    • Human tissue and cell based assays.
    - How to predict efficacy: measurement of mechanistic markers
    - Species differences – challenges identified
    • In vivo models of Asthma and COPD
    - Biomarker measurement
    - Pharmacodynamic models
    - Assessment of symptoms
    • Integrated drug discovery solutions
    - Networks in drug discovery
    - Providing outsourced services for Pharma clients

    15:30 Afternoon Tea

    15:50 Patient stratification: lesions from clinical trials of biologic drugs in Asthma

    Matthew Catley

    Matthew Catley, Head of Respiratory Pharmacology, UCB-Celltech

    • Biologics for the treatment of asthma
    • Anti-IL-5
    • Anti- IL-13
    • Biomarkers and patient stratification

    16:30 Panel Discussion: COPD mechanisms & treatments

    Peter Barnes

    Peter Barnes, Head of Respiratory Medicine, Imperial College

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.